Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 8, 2019

View Archived Issues

DKK2 unveiled as a potential therapeutic target for lung cancer

Where TH2 cells go, blood vessels are built

New metabolic syndrome target

Wild moms are good for offspring microbiome

First-in-human data presented for GSK-3036656

Recruitment ongoing in first in human trial of NOV-1601

JZP-458 to enter phase II/III development

Cleave Therapeutics obtains financing to advance its VCP/p97 inhibitor

BDGR-4 shows prophylactic and treatment potential for encephalitic alphaviruses

Cue Biopharma begins phase I study of CUE-101

Phase III data announced for setmelanotide in POMC and LEPR deficiency obesities

Phase I/II study of ASTX-295 recruiting participants

Serum visfatin as a diagnostic marker of patients with AMI

Apoptosis regulator Bcl-2 inhibitors patented by Zeno Royalties & Milestones

Changsha Hooz Bioscience & Technology compounds target UHRF1 and/or HDAC1

PI4KIII-beta inhibitors discovered at GlaxoSmithKline

Idorsia Pharmaceuticals describes C5aR antagonists

Favorable safety and PK data from phase Ib/IIa study of recombinant human plasma gelsolin

FDA grants approval to initiate phase Ib/II stud of L-DOS-47 plus doxorubicin in pancreatic cancer

Cancer Research UK and Hummingbird Bioscience to partner to advance HMBD-001

Servier enrolling subjects in first-in-human trial of S-65487

Chiesi Farmaceutici initiates phase I study of CHF-6523 in COPD

Novel T-cell subtype predicts risk of anaphylactic shock

Applied Therapeutics reports data from SAD portion of phase I/II study of AT-007

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...